IP Library Granted Patent US 9,441,017
Granted Patent B2
US 9,441,017 · App. 14/005,536 · Granted Sep 13, 2016

Water-soluble polypeptides comprised of repeat modules, method for preparing the same and method for a target-specific polypeptide and analysis of biological activity thereof

Inventors: Hak Sung Kim (Daejeon, KR); Dong Sup Kim (Daejeon, KR); Sang Chul Lee (Daejeon, KR); Byung Chul Lee (Seoul, KR); Ji Eun Han (Daejeon, KR); Joong Jae Lee (Daejeon, KR); Keun Wan Park (Daejeon, KR); Seung Pyo Hong (Daejeon, KR)
Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
C07K14/195C07K14/46C07K14/705C12N15/70C12Q1/6897G01N33/5023G06F19/16C07K2319/35C07K2319/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,441,017
App. No.
14/005,536
Granted
Sep 13, 2016
Kind
B2
Abstract

The present invention relates to a soluble polypeptide comprised of repeat modules. More particularly, the present invention relates to a soluble fusion polypeptide of the N-terminal domain of internalin and LRR (Leucine rich repeat) family protein, a method for preparing the polypeptide, a vector comprising a nucleic acid sequence encoding the polypeptide, a host cell comprising the vector, a method for producing a solubility and folding-improved fusion polypeptide by expressing the vector in the host cell, and a method for improving the solubility and folding of the fusion polypeptide. Further, the present invention relates to a method for preparing the polypeptide bound with a specific target and analyzing the efficacy of the soluble polypeptide.

Claims (7)

1. A water-soluble fusion polypeptide prepared by fusion of the N-terminal domain of internalin protein, and LRR (Leucine-rich repeat) family protein,

wherein the fusion polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:7, 8, 9, 10, 12, 15, 16, 17 and 18.

2. A method for analyzing the efficacy of the soluble fusion polypeptide of claim 1 , comprising the steps of:

(a) differentiating THP-1 cell line using PMA (phorbol 12-myristate 13-acetate);

(b) mixing in advance MD-2 (Myeloid differentiation protein-2), LPS (lipopolysaccharide), and the soluble fusion polypeptides of claim 1 so as to prepare mixtures;

(c) contacting the cell line of step (a) with the prepared mixtures of step (b); and

(d) determining that the soluble fusion polypeptide of claim 1 of the experimental group has better efficacy than that of the control group, when the experimental group contacted with the soluble fusion polypeptide of claim 1 shows a lower TNF-α (tumor necrosis factor alpha) level than the control group not contacted with the soluble fusion polypeptide of claim 1 to be analyzed.

Assignments (2)
LICENSE Recorded Feb 27, 2021
From: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
To: PROEN THERAPEUTICS INC.
Reel/Frame 055438/0533 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2013
From: KIM, HAK SUNG; KIM, DONG SUP; LEE, SANG CHUL; LEE, BYUNG CHUL; HAN, JI EUN; LEE, JOONE JAE; PARK, KEUN WAN; HONG, SEUNG PYO
To: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
Reel/Frame 031694/0935 →
Priority Claims (1)
KR 10-2011-0025446 · Mar 22, 2011 · national
Continuity (1)
Related Publication 20140088292A1 · Mar 27, 2014